PATENT CLAIM ANALYSIS

Application Number: 16255769
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "139100"]

Abstract:
Disclosed herein are antibodies specific to a delta1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells.

Claim (Index 19):
The method of  claim 18 , wherein the solid tumor is selected from the group consisting of pancreatic ductal adenocarcinoma (PDA), colorectal cancer (CRC), melanoma, breast cancer, lung cancer, glioblastoma, upper and lower gastrointestinal malignancies, carcinoid tumors, squamous cell head and neck cancer, genitourinary cancer, endometrial cancer, renal cancer, bladder cancer, prostate cancer, ovarian cancer, neuroendocrine cancer, adrenocortical cancer, and sarcomas.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 99.0
- Lexical Diversity: 1.38095
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16173970', '15271861', '16175453', '15034782', '15712010']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8140430710565819
- 35 USC 102 Novelty (BERT): 0.5521384710097913
- Combined Prediction Score: 0.7878526110519029
- Mean Citation Score: 435.944402
- Max Citation Score: 467.11746
- Similarity Product: 297.98864767621995

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test